Be the first to like this
Circularity Healthcare significantly updated Wound Care White Paper discussing mechanisms of action and diagnosis.
D`OXYVA® is able to produce a stable solution that is 50 times more highly concentrated than competing products. The vapor exits the water chamber and is almost imperceptibly misted onto the skin. Independent clinical research suggests that without the high CO2 content in the supersaturated vapor, it is not possible to generate such elevated blood flow and oxygenation levels and efficient transdermal delivery of molecules in the skin tissue. The increased presence of CO2 in the bloodstream auto-regulates the blood supply while inducing the Bohr Effect, attaching to red blood cells and ultimately leading to increased blood flow and oxygen delivery within the tissues. In a past IRB-approved human clinical study, the increased CO2 concentration significantly improved tissue perfusion (microcirculation) and blood flow locally and throughout the body in every subject often by over 100% without any adverse event, and D`OXYVA® has been recognized as a Non-Significant Risk (NSR) device. Therefore, the D`OXYVA® product is considered an "investigational device" when used for medical purposes and has an "investigational device exemption" ("IDE") status.